Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Sechaud, A. Drollmann, H. Hara, R. Karan, C. Boulton, L. Di Scala, A. Dmitriev, S. Villevalde, Z. Kobalava, G. Kaiser (Basel, Switzerland; Hyderabad, India; Horsham, United Kingdom; Moscow, Russian Federation). Small impact of mild and moderate renal impairment on the pharmacokinetics of inhaled NVA237. Eur Respir J 2012; 40: Suppl. 56, 4838

Member's Comments

Sechaud Romain - 03.09.2012 11:17
Excellent

Related content which might interest you: Lack of effect of mild and moderate hepatic impairment or UGT1A1 genotype on the pharmacokinetics of inhaled indacaterol Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 Evaluation of the bronchoprotective effects of salmetrol HFA and salmetrol CFC in adult patients with chronic stable mild to moderate asthma Source: Annual Congress 2009 - Airway hyperresponsiveness: mechanism and assessment Year: 2009 Efficacy and safety of single doses of inhaled LAS100977 in patients with mild to moderate asthma Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 The effects of adding in erdosteine on the routine bronchodilator therapy in moderate and severe COPD patients Source: Annual Congress 2006 - COPD therapy Year: 2006 Effects of adding salmeterol to inhaled corticosteroids on lung function and quality of life in patients with mild persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 499s Year: 2006 Once-daily tiotropium Respimat add-on therapy improves lung function in children with moderate symptomatic asthma, independent of the degree of airflow obstruction Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 The effect of long-term treatment with erdosteine on moderate or severe COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005 Comparison of efficacy and safety of Obucort Swinghaler with Pulmicot Turbuhaler in mild to moderate severe asthma patients Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010 The pharmacokinetics of inhaled NVA237 in COPD patients Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010 Efficacy and safety of oral sildenafil in cystic fibrosis childrenwith mild to moderate lung disease Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis Year: 2020 Patients with severe renal impairment do not require dose adjustment of roflumilast Source: Eur Respir J 2002; 20: Suppl. 38, 108s Year: 2002 Evaluation of the efficacy and safety of two formulations of Ipratropium bromide HFA pMDI in patients with mild to moderate chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2010 - COPD: treatment and monitoring Year: 2010 The bronchodilatory effect of NVA237 inhaled once daily in patients with COPD Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Bronchodilator efficacy of tiotropium in patients with mild COPD Source: Eur Respir J 2006; 28: Suppl. 50, 616s Year: 2006 Efficacy of tiotropium bromide inhalation combined with or without low dose theophylline for moderate to severe stable Chinese COPD patients Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 NVA237, a once-daily inhaled anticholinergic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006 Increased respiratory symptoms in COPD patients on withdrawal of therapy: evidence of long-term efficacy gains with formoterol turbuhaler Source: Eur Respir J 2002; 20: Suppl. 38, 243s Year: 2002 Effect of dupilumab on oral corticosteroid use in severe asthma patients with improving lung function Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma Year: 2020 Salmeterol/fluticasone therapy improves FEV1 in mild and moderate more than in severe COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 342s Year: 2004 Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013